Evidence map›Paper›PMID 30402141›Full record

ArticleHeart Asia2018

Cancer antigen-125 and outcomes in acute heart failure: a systematic review and meta-analysis.

Ka Hou Christien Li, Mengqi Gong, Guangping Li, Adrian Baranchuk, Tong Liu, Martin C S Wong, Aaron Jesuthasan, Rachel W C Lai, Jenny Chi Ling Lai, Alex Pui Wai Lee and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heart Asia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ka Hou Christien LiDepartment of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China.
Mengqi GongDepartment of Cardiology, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, china.
Guangping LiDepartment of Cardiology, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, china.
Adrian BaranchukDepartment of Medicine, Kingston General Hospital, Queen's University, Kingston, Ontario, Canada.
Tong LiuDepartment of Cardiology, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, china.
Martin C S WongJC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.
Aaron JesuthasanFaculty of Medicine, Newcastle University, England, UK.
Rachel W C LaiDepartment of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China.
Jenny Chi Ling LaiDepartment of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China.
Alex Pui Wai LeeDepartment of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China.
Antoni Bayés-GenisHeart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Rafael de la EspriellaCardiology Department, Hospital Clínico Universitario de Valencia, INCLIVA, Valencia, Spain.
Juan SanchisCardiology Department, Hospital Clínico Universitario de Valencia, INCLIVA, Valencia, Spain.
William K K WuFaculty of Medicine, Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, China.
Gary TseDepartment of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0001-5510-1253
Julio NuñezCardiology Department, Hospital Clínico Universitario de Valencia, INCLIVA, Valencia, Spain.
International Health Informatics Study (IHIS) Network

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCarbohydrate antigen-125 (CA125) is an ovarian cancer marker, but recent work has examined its role in risk stratification in heart failure. A recent meta-analysis examined its prognostic value in heart failure generally. However, there has been no systematic evaluation of its role specifically in acute heart failure (AHF).

methodsPubMed and EMBASE databases were searched until 11 May 2018 for studies that evaluated the prognostic value of CA125 in AHF.

resultsA total of 129 and 179 entries were retrieved from PubMed and EMBASE. Sixteen studies (15 cohort studies, 1 randomised trial) including 8401 subjects with AHF (mean age 71 years old, 52% male, mean follow-up 13 months, range of patients 525.1±598.2) were included. High CA125 levels were associated with a 68% increase in all-cause mortality (8 studies, HRs: 1.68, 95% CI 1.36 to 2.07; p<0.0001; I

conclusionOur meta-analysis found that high CA125 levels are associated with AHF symptoms, heart failure-related hospital readmissions and all-cause mortality. Therefore, CA125 emerges as a useful risk stratification tool for identifying high-risk patients with more severe fluid overload, as well as for monitoring following an AHF episode.

Indexed as

heart failureheart failure treatmentsystolic heart failure

Identifiers

PMID30402141
PMCPMC6204439

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.